Novel Agonists of Melatonin Receptors as Promising Hypotensive and Neuroprotective Agents for Therapy of Glaucomaстатья
Информация о цитировании статьи получена из
Web of Science,
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 24 октября 2018 г.
Аннотация:Melatonin analogs demonstrating affinity to melatonin receptors are promising candidates for application as antiglaucomatous agents. Chemical modification of the melatonin structure can increase efficiency, bioavailability, and selectivity of melatonin analogs. We have designed and synthesized a number of new 2-oxindole derivatives, the ligands of melatonin MT3 receptors; these analogs are characterized by the ability to lower intraocular pressure in normotensive rabbits and high antioxidant activity against hydroxyl radical and superoxide anion-radical. New ligands significantly exceeding melatonin in antioxidant activity can be also applicable for the development of therapeutic agents for treatment of oxidative stress. The maximal hypotensive effect of the analogs was comparable to and lasted longer than that of melatonin. Combination of these properties suggests potential used of the analyzed melatonin analogs in complex therapy of glaucoma.